Azenta, Inc. heads into its Q2 FY2026 earnings print on May 6 with one of the most aggressive short-interest buildups in the life sciences tools space.
Shorts have done most of the work in April. SI as a percentage of the free float has climbed from roughly 10.5% in late March to 15.5% today — a near-50% jump in under six weeks. That puts short interest among the more elevated readings across Azenta's peer group. Borrow conditions do not support the squeeze narrative: cost to borrow has eased to just 0.44%, down 16% on the week, and the ORTEX short score of 69 — while elevated — remains below recent highs. Availability is still relatively comfortable, meaning the lending pool is not yet under pressure. The options market adds little drama: the put/call ratio of 0.19 sits almost exactly at its 20-day average, signalling neither meaningful hedging demand nor outsized bullish call activity heading into the print.
The debate between bulls and bears hinges on whether Azenta's recovery story holds up at current valuations. Bulls point to strong EPS momentum — factor scores rank the company in the 82nd percentile on 30-day EPS momentum and the 73rd percentile on 12-month forward EPS growth — suggesting the estimate revision cycle has turned positive. Conestoga Capital added over 1.5 million shares in the most recent quarter, and Congress Asset Management added 860,000 shares, both meaningful votes of confidence from active managers. Bears, however, have been reinforced by Evercore ISI, which cut its price target from $45 to $35 in early April while keeping an Outperform rating — a flag that even a key bull has trimmed its ambitions. The stock, at $24.61, still trades at a meaningful discount to the analyst mean target of $35.40, but given the pattern of downward target revisions since January's upgrade cycle, the gap may overstate the consensus conviction.
History adds a caution note. The most recent comparable earnings event — February 2026 — delivered a 24.5% one-day collapse, followed by an additional 17.5% decline over the subsequent five days. That kind of reaction tends to leave scars: the short interest surge since mid-April looks consistent with institutional memory of that episode. The stock has recovered 8.7% over the past month and 1.5% on the week, a partial reversal that peers have not universally shared — PACB fell 3.1% on the day and BRKR declined 1.1%, while TEM gained 1.5%, leaving the group mixed.
The print will test whether Azenta's improving EPS trajectory can overcome the February overhang — and whether the bear conviction now embedded in 15.5% short interest was built on insight or anxiety.
See the live data behind this article on ORTEX.
Open AZTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
